Multiple Myeloma | Unmet Need | US/EU | 2016
The multiple myeloma market is becoming increasingly crowded. In 2015, several new, high-priced therapies have been approved for in the treatment of multiple myeloma, making this lucrative market more dynamic and competitive. Although these new therapies have significantly improved the outcomes for multiple myeloma, most patients relapse and ultimately die of their disease. Owing to the high level of unmet need in multiple myeloma, significant clinical and commercial opportunity remains for therapies that can provide greater survival benefits compared with current standards of care.
Related Market Assessment Reports
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
